Obesity-associated cancer: An immunological perspective

Proceedings of the Nutrition Society

Volumn 75, Issue 2, 2016, Pages 125-138

  Conroy, Melissa J ^a   Dunne, Margaret R ^a   Donohoe, Claire L ^a   Reynolds, John V ^a  

^a ST JAMES S HOSPITAL   (Ireland)

Author keywords

Cancer; Immunotherapeutics; Inflammation; Lymphocytes; Obesity

Indexed keywords

ADIPONECTIN; C REACTIVE PROTEIN; CD4 ANTIGEN; CD8 ANTIGEN; FATTY ACID; FIBRINOGEN; INSULIN; INTERLEUKIN 6; IPILIMUMAB; LEPTIN; NIVOLUMAB; PEMBROLIZUMAB; PLASMINOGEN ACTIVATOR INHIBITOR 1; ADIPOCYTOKINE; LYMPHOCYTE ANTIGEN RECEPTOR;

ADAPTIVE IMMUNITY; ADOPTIVE TRANSFER; ARTICLE; BODY MASS; BREAST CANCER; CANCER RESEARCH; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL COUNT; CELL ENERGY; CELL METABOLISM; CELL MIGRATION; COLON CANCER; DISEASE ASSOCIATION; GALLBLADDER CANCER; GAMMA DELTA T LYMPHOCYTE; HAZARD RATIO; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; INFLAMMATION; INNATE IMMUNITY; INSULIN RESISTANCE; KIDNEY CANCER; LEUKEMIA; LIFESTYLE MODIFICATION; LIVER CANCER; MACROPHAGE; MALIGNANT NEOPLASTIC DISEASE; METABOLIC REGULATION; MUCOSAL ASSOCIATED INVARIANT T LYMPHOCYTE; NATURAL KILLER CELL; NATURAL KILLER T CELL; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; OVARY CANCER; PANCREAS CANCER; PATHOPHYSIOLOGY; RECTUM CANCER; T LYMPHOCYTE; THYROID CANCER; TUMOR IMMUNITY; UTERINE CERVIX CANCER; UTERUS CANCER; ADOLESCENT; ADULT; COMPLICATION; IMMUNOLOGY; IMMUNOTHERAPY; NEOPLASMS; RISK FACTOR;

ADIPOKINES; ADOLESCENT; ADULT; BODY MASS INDEX; DIABETES MELLITUS, TYPE 2; HUMANS; IMMUNOTHERAPY; INFLAMMATION; INSULIN RESISTANCE; KILLER CELLS, NATURAL; MACROPHAGES; NEOPLASMS; OBESITY; RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA; RISK FACTORS; T-LYMPHOCYTES;

EID: 84947081036     PISSN: 00296651     EISSN: 14752719     Source Type: Journal    
DOI: 10.1017/S0029665115004176     Document Type: Article

References (169)

1. WHO. 2015, Obesity and overweight. Fact sheet. Available at: http://www.who.int/mediacentre/factsheets/fs311/en/.
2. Flegal KM, Carroll MD, Ogden CL &Curtin LR (2010) Prevalence and trends in obesity among US adults, 1999-2008. JAMA 303, 235-241.
3. Ogden CL, Carroll MD, Kit BK &Flegal KM (2014) Prevalence of childhood and adult obesity in the United States, 2011-2012. JAMA 311, 806-814; available from: http://www.ncbi.nlm.nih.gov/pubmed/24570244
4. Calle EE, Rodriguez C, Walker-Thurmond K &Thun MJ (2003) Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 348, 1625-1638.
5. Roberts DL, Dive C &Renehan AG (2010) Biological mechanisms linking obesity and cancer risk: new perspectives. Annu Rev Med 61, 301-316.
6. Scheen AJ &Luyckx FH (2002) Obesity and liver disease. Best Pr Res Clin 16, 703-716.
7. Goran MI, Ball GDC &Cruz ML (2003) Obesity and risk of type 2 diabetes and cardiovascular disease in children and adolescents. J Clin Endocrinol Metab 88, 1417-1427.
8. Renehan AG, Tyson M, Egger M, Heller RF &Zwahlen M (2008) Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 371, 569-578.
9. Beddy P, Howard J, McMahon C, Knox M, De Blacam C, Ravi N et al. (2010) Association of visceral adiposity with oesophageal and junctional adenocarcinomas. Br J Surg 97, 1028-1034.
10. Postow MA, Callahan MK &Wolchok JD (2015) Immune checkpoint blockade in cancer therapy. J Clin Oncol 33, 1974-1982; available from: http://jco.ascopubs. org/cgi/ doi/10.1200/JCO.2014.59.4358
11. World Cancer Research Fund (2007) Food, nutrition, physical activity, and the prevention of cancer: a global perspective. American Institute of Cancer Research.
12. Bhaskaran K, Douglas I, Forbes H, Dos-Santos-Silva I, Leon DA &Smeeth L (2014) Body-mass index and risk of 22 specific cancers: a population-based cohort study of 5•24 million UK adults. The Lancet 384, 755-765.
13. Reeves GK, Pirie K, Beral V, Green J, Spencer E &Bull D (2007) Cancer incidence and mortality in relation to body mass index in the million women study: cohort study. BMJ 335, 1134.
14. Calle EE &Kaaks R (2004) Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer 4, 579-591.
15. Hill AB (2015) The environment and disease: association or causation? 1965. J R Soc Med 108, 32-37; available from: http://www.ncbi.nlm.nih.gov/pubmed/25572993
16. Renehan AG, Egger M &Zwahlen M (2010) Body mass index and cancer risk: the evidence for causal association~! 2009-04-22~!2009-06-16~!2010-07-13~!. Open Obes J 2, 12-22; available from: http://www.bentham-open.org/ pages/content.php?TOOBESJ/2010/00000002/00000002/ 12TOOBESJ.SGM
17. Donohoe CL, Doyle SL &Reynolds JV (2011) Visceral adiposity, insulin resistance and cancer risk. Diabetol Metab Syndr 3, 12.
18. Donohoe CL, O'Farrell NJ, Doyle SL &Reynolds JV (2014) The role of obesity in gastrointestinal cancer: evidence and opinion. Therap Adv Gastroenterol 7, 38-50; available from: http://www.pubmedcentral.nih.gov/articlerender. fcgi?artid=3871278&tool=pmcentrez&render type=abstract
19. Fujioka S, Matsuzawa Y, Tokunaga K &Tarui S (1987) Contribution of intra-abdominal fat accumulation to the impairment of glucose and lipid metabolism in human obesity. Metabolism 36, 54-59.
20. Seidell JC, Björntorp P, Sjöström L, Kvist H &Sannerstedt R (1990) Visceral fat accumulation in men is positively associated with insulin, glucose, and C-peptide levels, but negatively with testosterone levels. Metabolism 39, 897-901.
21. Nakamura T, Tokunaga K, Shimomura I, Nishida M, Yoshida S, Kotani K et al. (1994) Contribution of visceral fat accumulation to the development of coronary artery disease in non-obese men. Atherosclerosis 107, 239-246.
22. Vague J (1956) The degree of masculine differentiation of obesities: a factor determining predisposition to diabetes, atherosclerosis, gout, and uric calculous disease. Am J Clin Nutr 4, 20-34.
23. Schapira DV, Clark RA, Wolff PA, Jarrett AR, Kumar NB &Aziz NM (1994) Visceral obesity and breast cancer risk. Cancer 74, 632-639.
24. Schoen RE, Tangen CM, Kuller LH, Burke GL, Cushman M &Tracy RP et al. (1999) Increased blood glucose and insulin, body size, and incident colorectal cancer. J Natl Cancer Inst 91, 1147-1154.
25. Yamaji T, Iwasaki M, Sasazuki S, Kurahashi N, Mutoh M, Yamamoto S et al. (2009) Visceral fat volume and the prevalence of colorectal adenoma. Am J Epidemiol 170, 1502-1511.
26. Nam SY, Kim BC, Han KS, Ryu KH, Park BJ, Kim HB et al. (2010) Abdominal visceral adipose tissue predicts risk of colorectal adenoma in both sexes. Clin Gastroenterol Hepatol 8, 443-50.e1-2.
27. Esposito K &Giugliano D (2004) The metabolic syndrome and inflammation: association or causation? Nutrition, metabolism, and cardiovascular diseases. NMCD 228-232.
28. Wajchenberg BL (2000) Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome. Endocr Rev 697-738.
29. Das UN (2001) Is obesity an inflammatory condition? Nutrition 953-966.
30. Coussens LM, Werb Z (2002) Inflammation and cancer. Nature 420, 860-867.
31. Xu H, Barnes GT, Yang Q, Tan G, Yang D, Chou CJ et al. (2003) Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 112, 1821-1830.
32. Hotamisligil GS, Arner P, Caro JF, Atkinson RL &Spiegelman BM (1995) Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest 95, 2409-2415.
33. Shoelson SE, Lee J &Goldfine AB (2006) Inflammation and insulin resistance. J Clin Invest 1793-1801.
34. Antuna-Puente B, Feve B, Fellahi S &Bastard J-P (2008) Adipokines: the missing link between insulin resistance and obesity. Diabetes Metab 34, 2-11.
35. DeFronzo RA (2010) Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard lecture 2009. Diabetologia 1270-1287.
36. Buchwald H, Avidor Y, Braunwald E, Jensen MD, Pories W, Fahrbach K et al. (2004) Bariatric surgery: a systematic review and meta-analysis. JAMA 292, 1724-1737.
37. Johnson JA, Carstensen B, Witte D, Bowker SL, Lipscombe L &Renehan AG (2012) Diabetes and cancer (1): evaluating the temporal relationship between type 2 diabetes and cancer incidence. Diabetologia 1607-1618.
38. Bergman RN &Ader M (2000) Free fatty acids and pathogenesis of type 2 diabetes mellitus. Trends Endocrinol Metab 11, 351-356.
39. Moller DE &Flier JS (1991) Insulin resistance-mechanisms, syndromes, and implications. N Engl J Med 325, 938-948.
40. Trevisan M, Liu J, Muti P, Misciagna G, Menotti A &Fucci F (2001) Markers of insulin resistance and colorectal cancer mortality. Cancer Epidemiol Biomarkers Prev 10, 937-941.
41. Colangelo LA, Gapstur SM, Gann PH, Dyer AR &Liu K (2002) Colorectal cancer mortality and factors related to the insulin resistance syndrome. Cancer Epidemiol Biomarkers Prev 11, 385-391.
42. Pollak M (2012) The insulin and insulin-like growth factor receptor family in neoplasia: an update. Nat Rev Cancer.
43. Hellawell GO, Turner GDH, Davies DR, Poulsom R, Brewster SF &Macaulay VM (2002) Expression of the type 1 insulin-like growth factor receptor is up-regulated in primary prostate cancer and commonly persists in metastatic disease. Cancer Res 62, 2942-2950.
44. Law JH, Habibi G, Hu K, Masoudi H, Wang MYC, Stratford AL et al. (2008) Phosphorylated insulin-like growth factor-I/insulin receptor is present in all breast cancer subtypes and is related to poor survival. Cancer Res 68, 10238-10246.
45. Donohoe CL, Doyle SL, McGarrigle S, Cathcart MC, Daly E, O'Grady A et al. (2012) Role of the insulin-like growth factor 1 axis and visceral adiposity in oesophageal adenocarcinoma. Br J Surg 99, 387-396; available from: http://www.ncbi.nlm.nih.gov/pubmed/22241325
46. Tsilidis KK, Travis RC, Appleby PN, Allen NE, Lindstrom S, Schumacher FR et al. (2012) Interactions between genome-wide significant genetic variants and circulating concentrations of insulin-like growth factor 1, sex hormones, and binding proteins in relation to prostate cancer risk in the national cancer institute breast and prostate cancer. Am J Epidemiol 175, 926-935.
47. Hanahan D &Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144, 646-674; available from: http://www.ncbi.nlm.nih.gov/pubmed/21376230
48. Lynam-Lennon N, Maher SG, Maguire A, Phelan J, Muldoon C, Reynolds JV et al. (2014) Altered mitochondrial function and energy metabolism is associated with a radio resistant phenotype in oesophageal adenocarcinoma. PLoS ONE 9 (6) e100738.
49. Groff JL, Stugard CE, Mays CJ, Koopmans HS &DiGirolamo M (1992) Glucose metabolism in isolated rat adipocytes: estimate of total recovery by the product summation method. J Lab Clin Med 119, 216-220.
50. Lukanova A, Lundin E, Zeleniuch-Jacquotte A, Muti P, Mure A, Rinaldi S et al. (2004) Body mass index, circulating levels of sex-steroid hormones, IGF-I and IGF-binding protein-3: a cross-sectional study in healthy women. Eur J Endocrinol 150, 161-171.
51. Zeleniuch-Jacquotte A, Akhmedkhanov A, Kato I, Koenig KL, Shore RE, Kim MY et al. (2001) Postmenopausal endogenous oestrogens and risk of endometrial cancer: Results of a prospective study. Br J Cancer 84, 975-981.
52. Dossus L, Lukanova A, Rinaldi S, Allen N, Cust AE, Becker S et al. (2013) Hormonal, metabolic, and inflammatory profiles and endometrial cancer risk within the EPIC cohort-A factor analysis. Am J Epidemiol 177, 787-799.
53. Cao H (2014) Adipokines in obesity and metabolic disease. J Endocrinol 220, T47-T59.
54. Maffei M, Halaas J, Ravussin E, Pratley RE, Lee GH, Zhang Y et al. (1995) Leptin levels in human and rodent: measurement of plasma leptin and ob RNA in obese and weight-reduced subjects. Nat Med 1, 1155-1161.
55. Lord GM, Matarese G, Howard JK, Baker RJ, Bloom SR &Lechler RI (1998) Leptin modulates the T-cell immune response and reverses starvation-induced immunosuppression. Nature 394, 897-901.
56. Matarese G, Moschos S &Mantzoros CS (2005) Leptin in immunology. J Immunol 174, 3137-3142; available from: http://www.jimmunol.org/cgi/doi/10.4049/jimmunol. 174.6.3137
57. Faggioni R, Feingold KR &Grunfeld C (2001) Leptin regulation of the immune response and the immunodeficiency of malnutrition. FASEB J 15, 2565-2571.
58. Tanaka S, Isoda F, Ishihara Y, Kimura M &Yamakawa T (2001) T lymphopaenia in relation to body mass index and TNF-alpha in human obesity: adequate weight reduction can be corrective. Clin Endocrinol (Oxf) 54, 347-354.
59. Considine RV, Sinha MK, Heiman ML, Kriauciunas A, Stephens TW, Nyce MR et al. (1996) Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med 334, 292-295.
60. Kadowaki T &Yamauchi T (2005) Adiponectin and adiponectin receptors. Endocr Rev 439-451.
61. Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE et al. (2001) Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 86, 1930-1935.
62. Yamauchi T, Kamon J, Waki H, Terauchi Y, Kubota N, Hara K et al. (2001) The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 7, 941-946.
63. Lago F, Dieguez C, Gómez-Reino J &Gualillo O (2007) Adipokines as emerging mediators of immune response and inflammation. Nat Clin Pract Rheumatol 3, 716-724; available from: http://www.nature.com/doifinder/10.1038/ ncprheum0674
64. Fain JN (2006) Release of interleukins and other inflammatory cytokines by human adipose tissue is enhanced in obesity and primarily due to the nonfat cells. Vitam Horm 74, 443-477.
65. Lysaght J, Allott EH, Donohoe CL, Howard JM, Pidgeon GP, Reynolds JV (2011) T lymphocyte activation in visceral adipose tissue of patients with oesophageal adenocarcinoma. Br J Surg 98, 964-974.
66. Lysaght J, van der Stok EP, Allott EH, Casey R, Donohoe CL, Howard JM et al. (2011) Pro-inflammatory and tumour proliferative properties of excess visceral adipose tissue. Cancer Lett 312, 62-72.
67. Lutz CT, Quinn LS (2012) Sarcopenia, obesity, and natural killer cell immune senescence in aging: altered cytokine levels as a common mechanism. Aging 4, 535-546.
68. Wellen KE, Hotamisligil GS (2003) Obesity-induced inflammatory changes in adipose tissue. J Clin Invest 1785-1788.
69. Karin M (2009) NF-kappaB as a critical link between inflammation and cancer. Cold Spring Harb Perspect Biol. 1, a000141.
70. Ramos-Nino ME (2013) The role of chronic inflammation in obesity-associated cancers. ISRN Oncol 1-25; available from: http://www.hindawi.com/isrn/oncology/2013/697521
71. Zhang X, Zhou M, Guo Y, Song Z &Liu B (2015) 1,25-Dihydroxyvitamin D3 promotes high glucose-induced M1 macrophage switching to M2 via the VDR-PPARγ signaling pathway. Biomed Res Int 157834; available from: http://www.ncbi.nlm.nih.gov/pubmed/25961000
72. Fridlender ZG, Jassar A, Mishalian I, Wang L-C, Kapoor V, Cheng G et al. (2013) Using macrophage activation to augment immunotherapy of established tumours. Br J Cancer 108, 1288-1297.
73. Winer S, Chan Y, Paltser G, Truong D, Tsui H, Bahrami J et al. (2009) Normalization of obesity-associated insulin resistance through immunotherapy. Nat Med 15, 921-929.
74. Knutson KL &Disis ML (2005) Tumor antigen-specific T helper cells in cancer immunity and immunotherapy. Cancer Immunol Immunother 721-728.
75. Zanetti M (2015) Tapping CD4 T cells for cancer immunotherapy: the choice of personalized genomics. J Immunol 194, 2049-2056; available from: http://www.ncbi.nlm.nih. gov/pubmed/25710958
76. Deiuliis J, Shah Z, Shah N, Needleman B, Mikami D, Narula V et al. (2011) Visceral adipose inflammation in obesity is associated with critical alterations in tregulatory cell numbers. Brusic V, editor. PLoS ONE 6, e16376; available from: http://dx.plos.org/10.1371/journal.pone.0016376
77. Bertola A, Ciucci T, Rousseau D, Bourlier V, Duffaut C, Bonnafous S et al. (2012) Identification of adipose tissue dendritic cells correlated with obesity-associated insulinresistance and inducing Th17 responses in mice and patients. Diabetes 61, 2238-2247.
78. Zou W &Restifo NP (2010) T(H)17 cells in tumour immunity and immunotherapy. Nat Rev Immunol 10, 248-256.
79. Nishikawa H, Sakaguchi S (2014) Regulatory T cells in cancer immunotherapy. Curr Opin Immunol 1-7.
80. Nishimura S, Manabe I, Nagasaki M, Eto K, Yamashita H, Ohsugi M et al. (2009) CD8+ effector T cells contribute to macrophage recruitment and adipose tissue inflammation in obesity. Nat Med 15, 914-920.
81. Jackson SR, Yuan J &Teague RM (2014) Targeting CD8+ T-cell tolerance for cancer immunotherapy. Immunotherapy 6, 833-852; available from: http://www.ncbi.nlm.nih. gov/pubmed/25290416
82. Klebanoff CA, Gattinoni L &Restifo NP (2006) CD8+ T-cell memory in tumor immunology and immunotherapy. Immunol Rev 211, 214-224; available from: http://www. pubmedcentral.nih.gov/articlerender.fcgi?artid=1501075 &tool=pmcentrez&rendertype=abstract
83. Lynch LA, O'Connell JM, Kwasnik AK, Cawood TJ, O'Farrelly C &O'Shea DB (2009) Are natural killer cells protecting the metabolically healthy obese patient? Obesity (Silver Spring) 17, 601-605.
84. Ljunggren H-G &Malmberg K-J (2007) Prospects for the use of NK cells in immunotherapy of human cancer. Nat Rev Immunol 7, 329-339.
85. Kawano T, Nakayama T, Kamada N, Kaneko Y, Harada M, Ogura N et al. (1999) Antitumor cytotoxicity mediated by ligand-activated human Vα24 NKT cells. Cancer Res 59, 5102-5105.
86. Schilbach K, Frommer K, Meier S, Handgretinger R, Eyrich M (0000) Immune response of human propagated gammadelta-T-cells to neuroblastoma recommend the Vdelta1+ subset for gammadelta-T-cell-based immunotherapy. J Immunother 31, 896-905.
87. Costanzo AE, Taylor KR, Dutt S, Han PP, Fujioka K &Jameson JM (2015) Obesity impairs γδ T cell homeostasis and antiviral function in humans. PLoS ONE 10, e0120918; available from: http://www.ncbi.nlm.nih.gov/ pubmed/25785862
88. Gomes AQ, Martins DS &Silva-Santos B (2010) Targeting γδ T lymphocytes for cancer immunotherapy: from novel mechanistic insight to clinical application. Cancer Res 70, 10024-10027; available from: http://www.ncbi.nlm.nih. gov/pubmed/21159627
89. Carolan E, Tobin LM, Mangan BA, Corrigan M, Gaoatswe G, Byrne G et al. (2015) Altered distribution and increased IL-17 production by mucosal-associated invariant T cells in adult and childhood obesity. J Immunol 194, 5775-5780; available from: http://www.ncbi.nlm.nih. gov/pubmed/25980010
90. Magalhaes I, Pingris K, Poitou C, Bessoles S, Venteclef N, Kiaf B et al. (2015) Mucosal-associated invariant T cell alterations in obese and type 2 diabetic patients. J Clin Invest 125, 1752-1762; available from: http://www.ncbi. nlm.nih.gov/pubmed/25751065
91. Ikeda H, Chamoto K, Tsuji T, Suzuki Y, Wakita D, Takeshima T et al. (2004) The critical role of type-1 innate and acquired immunity in tumor immunotherapy. Cancer Sci 697-703.
92. Foster PS, Martinez-Moczygemba M, Huston DP &Corry DB (2002) Interleukins-4,-5, and-13: emerging therapeutic targets in allergic disease. Pharmacol Ther 253-264.
93. Ciric B, El-behi M, Cabrera R, Zhang G-X &Rostami A (2009) IL-23 drives pathogenic IL-17-producing CD8+ T cells. J Immunol 182, 5296-5305; available from: http:// www.jimmunol.org/cgi/doi/10.4049/jimmunol.0900036
94. Cottrez F &Groux H (2001) Regulation of TGF-beta response during T cell activation is modulated by IL-10. J Immunol 167, 773-778.
95. Kalams SA &Walker BD (1998) The critical need for CD4 help in maintaining effective cytotoxic T lymphocyte responses. J Exp Med 188, 2199-2204.
96. Kono K, Kawaida H, Takahashi A, Sugai H, Mimura K, Miyagawa N et al. (2006) CD4(+)CD25high regulatory T cells increase with tumor stage in patients with gastric and esophageal cancers. Cancer Immunol Immunother 55, 1064-1071.
97. Shen Z, Zhou S, Wang Y, Li RL, Zhong C, Liang C et al. (2010) Higher intratumoral infiltrated Foxp3+ Treg numbers and Foxp3+/CD8+ ratio are associated with adverse prognosis in resectable gastric cancer. J Cancer Res Clin Oncol 136, 1585-1595.
98. Feuerer M, Herrero L, Cipolletta D, Naaz A, Wong J, Nayer A et al. (2009) Lean, but not obese, fat is enriched for a unique population of regulatory T cells that affect metabolic parameters. Nat Med 15, 930-939.
99. Robertson MJ &Ritz J (1990) Biology and clinical relevance of human natural killer cells. Blood 76, 2421-2438.
100. Harizi H (2013) Reciprocal crosstalk between dendritic cells and natural killer cells under the effects of PGE2 in immunity and immunopathology. Cell Mol Immunol 10, 213-221; available from: http://www.ncbi.nlm.nih.gov/ pubmed/23524652
101. Ing R &Stevenson MM (2009) Dendritic cell and NK cell reciprocal cross talk promotes gamma interferondependent immunity to blood-stage Plasmodium chabaudi AS infection in mice. Infect Immun 77, 770-782.
102. Yadav PK, Chen C, Liu Z (2011) Potential Role of NK Cells in the pathogenesis of inflammatory bowel disease. J Biomed Biotechnol 1-6; available from: http://www.hindawi. com/journals/bmri/2011/348530
103. Gardiner CM &Dunphy S (2011) NK cells and psoriasis. J Biomed Biotechnol. Available from: http://dx.doi.org/ 10.1155/2011/248317
104. O'Shea D, Cawood TJ, O'Farrelly C &Lynch L (2010) Natural killer cells in obesity: impaired function and increased susceptibility to the effects of cigarette smoke. PLoS ONE 5.
105. O'Rourke RW, Gaston GD, Meyer KA, White AE &Marks DL (2013) Adipose tissue NK cells manifest an activated phenotype in human obesity. Metabolism 62, 1557-1561.
106. O'Rourke RW (2014) Obesity and cancer: at the crossroads of cellular metabolism and proliferation. Surg Obes Relat Dis 10, 1208-1219; available from: http:// www.ncbi.nlm.nih.gov/pubmed/25264328
107. Wensveen FM, Jelenčić V, Valentić S, Šestan M, Wensveen TT, Theurich S et al. (2015) NK cells link obesity-induced adipose stress to inflammation and insulin resistance. Nat Immunol 16; available from: http://www. ncbi.nlm.nih.gov/pubmed/25729921
108. Bendelac A, Rivera MN, Park SH, Roark JH (1997) Mouse CD1-specific NK1 T cells: development, specificity, and function. Annu Rev Immunol 15, 535-562.
109. Exley M, Garcia J, Balk SP &Porcelli S (1997) Requirements for CD1d recognition by human invariant Valpha24+ CD4-CD8-T cells. J Exp Med 186, 109-120.
110. Brigl M &Brenner MB (2004) CD1: antigen presentation and T cell function. Annu Rev Immunol 22, 817-890.
111. Gumperz JE (2006) The ins and outs of CD1 molecules: bringing lipids under immunological surveillance. Traffic 2-13.
112. Kawano T, Cui J, Koezuka Y, Toura I, Kaneko Y, Motoki K et al. (1997) CD1d-restricted and TCRmediated activation of valpha14 NKT cells by glycosylceramides. Science 278, 1626-1629.
113. Kenna T, Golden-Mason L, Norris S, Hegarty JE, O'Farrelly C &Doherty DG (2004) Distinct subpopulations of gamma delta T cells are present in normal and tumor-bearing human liver. Clin Immunol 113, 56-63; available from: http://www.ncbi.nlm.nih.gov/pubmed/ 15380530
114. Lynch L, Nowak M, Varghese B, Clark J, Hogan AE, Toxavidis V et al. (2012) Adipose tissue invariant NKT cells protect against diet-induced obesity and metabolic disorder through regulatory cytokine production. Immunity 37, 574-587; available from: http://lin kinghub.elsevier.com/retrieve/pii/S1074761312003792
115. Dunne MR, Elliott L, Hussey S, Mahmud N, Kelly J, Doherty DG et al. (2013) Persistent changes in circulating and intestinal γδ T cell subsets, invariant natural killer T cells and mucosal-associated invariant T cells in children and adults with coeliac disease. PLoS ONE 8, e76008.
116. Laggner U, Di Meglio P, Perera GK, Hundhausen C, Lacy KE, Ali N et al. (2011) Identification of a novel proinflammatory human skin-homing Vγ9 Vδ2 T cell subset with a potential role in psoriasis. J Immunol 187, 2783-2793.
117. Lahn M (2000) The role of gammadelta T cells in the airways. J Mol Med (Berl) 78, 409-425.
118. Exley MA &Boyson JE (2011) Protective role of regulatory decidual γδ T cells in pregnancy. Clin Immunol 141, 236-239.
119. Hayday AC (2000) [gamma][delta] cells: a right time and a right place for a conserved third way of protection. Annu Rev Immunol 18, 975-1026.
120. Dunne MR, Mangan BA, Madrigal-Estebas L &Doherty DG (2010) Preferential Th1 cytokine profile of phosphoantigen-stimulated human Vγ9Vδ2 T cells. Mediators Inflamm 704941.
121. Crowley MP, Reich Z, Mavaddat N, Altman JD &Chien Y (1997) The recognition of the nonclassical major histocompatibility complex (MHC) class I molecule, T10, by the gammadelta T cell, G8. J Exp Med 185, 1223-1230.
122. Singhal A, Mori L, De Libero GT (2013) cell recognition of non-peptidic antigens in infectious diseases. Indian J Med Res 620-631.
123. Lockhart E, Green AM &Flynn JL (2006) IL-17 production is dominated by gammadelta T cells rather than CD4 T cells during Mycobacterium tuberculosis infection. J Immunol 177, 4662-4669.
124. Bergstresser PR, Sullivan S, Streilein JW &Tigelaar RE (1985) Origin and function of Thy-1+ dendritic epidermal cells in mice. J Invest Dermatol 85(Suppl. 1), 85s-90s.
125. Siegers GM, Dhamko H, Wang X-H, Mathieson AM, Kosaka Y, Felizardo TC et al. (2011) Human Vδ1 γδ T cells expanded from peripheral blood exhibit specific cytotoxicity against B-cell chronic lymphocytic leukemiaderived cells. Cytotherapy 13, 753-764.
126. Mangan BA, Dunne MR, O'Reilly VP, Dunne PJ, Exley MA, O'Shea D et al. (2013) Cutting edge: CD1d restriction and Th1/Th2/Th17 cytokine secretion by human Vδ3 T cells. J Immunol 191, 30-34; available from: http://www.ncbi.nlm.nih.gov/pubmed/23740951
127. Mehta P, Nuotio-Antar AM &Smith CW (2015) γδ T cells promote inflammation and insulin resistance during high fat diet-induced obesity in mice. J Leukoc Biol 97, 121-134; available from: http://www.ncbi.nlm.nih.gov/ pubmed/25395302
128. Treiner E, Duban L, Bahram S, Radosavljevic M, Wanner V, Tilloy F et al. (2003) Selection of evolutionarily conserved mucosal-associated invariant T cells by MR1. Nature 422, 164-169; available from: http://www. ncbi.nlm.nih.gov/pubmed/12634786
129. Dusseaux M, Martin E, Serriari N, Péguillet I, Premel V, Louis D et al. (2011) Human MAIT cells are xenobioticresistant, tissue-targeted, CD161hi IL-17-secreting T cells. Blood 117, 1250-1259; available from: http://www.ncbi. nlm.nih.gov/pubmed/21084709
130. Le Bourhis L, Dusseaux M, Bohineust A, Bessoles S, Martin E, Premel V et al. (2013) MAIT cells detect and efficiently lyse bacterially-infected epithelial cells. PLoS Pathog 9.
131. Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A &Locati M (2004) The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol 677-686.
132. Verreck FAW, de Boer T, Langenberg DML, Hoeve MA, Kramer M, Vaisberg E et al. (2004) Human IL-23-producing type 1 macrophages promote but IL-10-producing type 2 macrophages subvert immunity to (myco)bacteria. Proc Natl Acad Sci USA 101, 4560-4565.
133. Lamagna C, Aurrand-Lions M &Imhof BA (2006) Dual role of macrophages in tumor growth and angiogenesis. J Leukoc Biol 80, 705-713.
134. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL &Ferrante AW (2003) Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 112, 1796-1808.
135. Patsouris D, Li PP, Thapar D, Chapman J, Olefsky JM &Neels JG (2008) Ablation of CD11c-positive cells normalizes insulin sensitivity in obese insulin resistant animals. Cell Metab 8, 301-309.
136. Surmi BK, Webb CD, Ristau AC &Hasty AH (2010) Absence of macrophage inflammatory protein-1{alpha} does not impact macrophage accumulation in adipose tissue of diet-induced obese mice. Am J Physiol Endocrinol Metab 299, E437-E445.
137. Ota T (2013) Chemokine systems link obesity to insulin resistance. Diabetes Metab J 37, 165-172.
138. Ostuni R, Kratochvill F, Murray PJ, Natoli G (2015) Macrophages and cancer: from mechanisms to therapeutic implications. Trends Immunol 36, 229-239; available from: http://www.ncbi.nlm.nih.gov/pubmed/ 25770924
139. Mockler MB, Conroy MJ &Lysaght J (2014) Targeting T cell immunometabolism for cancer immunotherapy; understanding the impact of the tumor microenvironment. Front Oncol 4; available from: http://journal.frontiersin. org/article/10.3389/fonc.2014.00107/abstract
140. Fox CJ, Hammerman PS &Thompson CB (2005) Fuel feeds function: energy metabolism and the T-cell response. Nat Rev Immunol 5, 844-852.
141. Pearce E &Pearce E (2013) Metabolic pathways in immune cell activation and quiescence. Immunity 633-643.
142. Guppy M, Greiner E &Brand K (1993) The role of the Crabtree effect and an endogenous fuel in the energy metabolism of resting and proliferating thymocytes. Eur J Biochem 212, 95-99.
143. Greiner EF, Guppy M &Brand K (1994) Glucose is essential for proliferation and the glycolytic enzyme induction that provokes a transition to glycolytic energy production. J Biol Chem 269, 31484-31490.
144. Carr EL, Kelman A, Wu GS, Gopaul R, Senkevitch E, Aghvanyan A et al. (2010) Glutamine uptake and metabolism are coordinately regulated by ERK/MAPK during T lymphocyte activation. J Immunol 185, 1037-1044; available from: http://www.jimmunol.org/cgi/doi/10.4049/ jimmunol.0903586
145. Van Stipdonk MJB, Hardenberg G, Bijker MS, Lemmens EE, Droin NM, Green DR et al. (2003) Dynamic programming of CD8+ T lymphocyte responses. Nat Immunol 4, 361-365.
146. Bental M &Deutsch C (1993) Metabolic changes in activated T cells: an NMR study of human peripheral blood lymphocytes. Magn Reson Med 29, 317-326.
147. Pearce EL, Walsh MC, Cejas PJ, Harms GM, Shen H, Wang L-S et al. (2009) Enhancing CD8 T-cell memory by modulating fatty acid metabolism. Nature 460, 103-107.
148. Michalek RD, Gerriets VA, Jacobs SR, Macintyre AN, MacIver NJ, Mason EF et al. (2011) Cutting edge: distinct glycolytic and lipid oxidative metabolic programs are essential for effector and regulatory CD4+ T cell subsets. J Immunol 186, 3299-3303.
149. Gregor MF, Hotamisligil GS (2011) Inflammatory mechanisms in obesity. Annu Rev Immunol 29, 415-445; available from: http://www.annualreviews.org/doi/abs/10. 1146/annurev-immunol-031210-101322
150. Gilbert Ca, Slingerland JM (2013) Cytokines, obesity, and cancer: new insights on mechanisms linking obesity to cancer risk and progression. Annu Rev Med 64, 45-57; available from: http://www.ncbi.nlm.nih.gov/pubmed/ 23121183
151. O'Neill LAJ (2015) A broken krebs cycle in macrophages. Immunity 42, 393-394; available from: http://linkinghub. elsevier.com/retrieve/pii/S1074761315000928
152. Murray PJ, Allen JE, Biswas SK, Fisher EA, Gilroy DW, Goerdt S et al. (2014) Macrophage activation and polarization: nomenclature and experimental guidelines. Immunity 41, 14-20.
153. Lin JT, Stein EA, Wong MT, Kalpathy KJ, Su LL, Utz PJ et al. (2012) Differential mTOR and ERK pathway utilization by effector CD4 T cells suggests combinatorial drug therapy of arthritis. Clin Immunol 142, 127-138.
154. Wu D, Wu P, Huang Q, Liu Y, Ye J &Huang J (2013) Interleukin-17: a promoter in colorectal cancer progression. Clin Dev Immunol 436307; available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi? artid=3870650&tool=pmcentrez&rendertype=abstract
155. Crompton JG, Sukumar M, Roychoudhuri R, Clever D, Gros A, Eil RL et al. (2015) Akt inhibition enhances expansion of potent tumor-specific lymphocytes with memory cell characteristics. Cancer Res 75, 296-305; available from: http://www.ncbi.nlm.nih.gov/pubmed/25432172
156. Crompton JG, Sukumar M &Restifo NP (2014) Uncoupling T-cell expansion from effector differentiation in cell-based immunotherapy. Immunol Rev 257, 264-276.
157. Chlebowski RT, Blackburn GL, Thomson CA, Nixon DW, Shapiro A, Hoy MK et al. (2006) Dietary fat reduction and breast cancer outcome: interim efficacy results from the women's intervention nutrition study. J Natl Cancer Inst 98, 1767-1776.
158. Griggs JJ &Sabel MS (2008) Obesity and cancer treatment: weighing the evidence. J Clin Oncol 26, 4060-4062; available from: http://jco.ascopubs.org/cgi/doi/10. 1200/JCO.2008.17.4250
159. Schmitz KH, Neuhouser ML, Agurs-Collins T, Zanetti KA, Cadmus-Bertram L, Dean LT et al. (2013) Impact of obesity on cancer survivorship and the potential relevance of race and ethnicity. JNCI J Natl Cancer Inst 105, 1344-1354; available from: http://jnci.oxfordjournals. org/cgi/doi/10.1093/jnci/djt223
160. Curiel TJ, Wei S, Dong H, Alvarez X, Cheng P, Mottram P et al. (2003) Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat Med 9, 562-567; available from: http://www.nature.com/doifinder/ 10.1038/nm863
161. Mirsoian A, Bouchlaka MN, Sckisel GD, Chen M, Pai C-CS, Maverakis E et al. (2014) Adiposity induces lethal cytokine storm after systemic administration of stimulatory immunotherapy regimens in aged mice. J Exp Med 211, 2373-2383; available from: http://www.ncbi.nlm. nih.gov/pubmed/25366964
162. Wennerberg E, Kremer V, Childs R &Lundqvist A (2015) CXCL10-induced migration of adoptively transferred human natural killer cells toward solid tumors causes regression of tumor growth in vivo. Cancer Immunol Immunother 64, 225-235.
163. Winer S & Winer DA (2012) The adaptive immune system as a fundamental regulator of adipose tissue inflammation and insulin resistance. Immunol Cell Biol 90, 755-762.
164. Pagès F, Berger A, Camus M, Sanchez-Cabo F, Costes A, Molidor R et al. (2005) Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med 353, 2654-2666.
165. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pagès C et al. (2006) Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313, 1960-1964; available from: http://www.ncbi.nlm.nih.gov/ pubmed/17008531
166. Park JH, McMillan DC, Powell AG, Richards CH, Horgan PG, Edwards J et al. (2015) Evaluation of a tumor microenvironment-based prognostic score in primary operable colorectal cancer. Clin Cancer Res 21, 882-888; available from: http://www.ncbi.nlm.nih.gov/ pubmed/25473000
167. Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky JM, Desrichard A et al. (2014) Genetic basis for clinical response to CTLA-4 blockade in Melanoma. N Engl J Med available from: http://www.ncbi.nlm.nih.gov/ pubmed/25409260
168. Curran MA, Montalvo W, Yagita H &Allison JP (2010) PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci USA 107, 4275-4280.
169. Drake CG (2012) Combination immunotherapy approaches. Ann Oncol. 23, Suppl. 8, vii 41-46.